Why Your Cycle Was Delayed: — Kidney and Liver Results

No. A kidney or liver result that pauses your cycle is information about how your body is processing the treatment, not about what the cancer is doing. Tumour status is assessed through scans and tumour markers on a separate schedule. Cycle delays caused by organ function readings are common and anticipated on many regimens — they do not change what the treatment is trying to achieve.

Most patients wait one to two weeks before the result is rechecked. If the reading has returned to the required range, the cycle proceeds. If it has not, your team will decide whether a further short wait, a dose adjustment, or a change to the regimen is the right next step. There is no fixed answer because the pace of recovery depends on the cause, the specific drug, and how your body responds.

This is a reasonable concern and worth raising directly with your oncologist. ASCO and NCCN guidance supports dose adjustment for organ function as a way to keep treatment continuing safely rather than stopping it entirely. Your oncologist will weigh the adjustment against what your regimen is intended to achieve for your specific situation. Do not ask for the standard dose to be given against medical advice — that decision belongs entirely with your treating team.

Some chemotherapy drugs do cause kidney or liver stress as a known and anticipated side effect. Cisplatin, for example, is nephrotoxic — meaning it can affect kidney function — and your team monitors creatinine and eGFR at every cycle precisely because of this. Some drugs are metabolised through the liver and can raise enzyme levels temporarily. The monitoring exists because these effects are expected, not because something has gone wrong. Your team will know which drugs in your regimen carry this risk.

Staying well hydrated is the most consistently useful step for kidney function in particular. Tell your team about every medicine, supplement, or remedy you are taking — including Ayurvedic, herbal, and over-the-counter products — because some of these affect kidney or liver clearance in ways that are not obvious. Your team may advise temporarily pausing a non-cancer medication if it is contributing to the result. Do not stop or change any medication without asking first.

If organ function does not recover to the threshold your regimen requires, your oncologist will consider whether a dose reduction, a switch to a less organ-demanding drug, or a different treatment approach is the right response. Some patients with pre-existing kidney or liver disease are managed on adjusted doses from the start of treatment. Being on a modified regimen is not the same as running out of options — it means the treatment has been adapted to what your body can handle safely.